Provided herein are cells, vectors and viruses in association with a mutant polypeptides that have emerged in response to a therapeutic or prophylactic agent to cancer compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response. In other examples, the mutant polypeptides comprise one or more or a combination of the following escape mutations T315I, E255K and M351T.本文提供與一種對癌症治療或預防劑反應所出現之突變多肽結合之細胞、載體及病毒;包含該等細胞、載體及病毒之組合物,及其用於誘發對該突變多肽之免疫反應之方法。在一些實例中,該免疫反應係細胞免疫反應。在其他實例中,該突變多肽包含脫逃突變T315I、E255K及M351T之一或多者或組合。
